Brief: Blueprint Medicines' Harbor Part 1 Trial Data In Indolent Systemic Mastocytosis Showed Elenestinib Was Well-Tolerated
09/12/2023 23:56
Dec 9 (Reuters) - Blueprint Medicines Corp BPMC.O :
* HARBOR PART 1 TRIAL DATA IN INDOLENT SYSTEMIC MASTOCYTOSIS
SHOWED ELENESTINIB WAS WELL-TOLERATED
Source text for Eikon: ID:nPn7NyJvGa
Further company coverage: BPMC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G